NMN and resveratrol are sold together so consistently that most people assume they are variations on one idea. They are not. They are different molecules from different research traditions, and the only thing binding them is a mechanistic story from the 2000s that has aged unevenly.
The story goes like this. Sirtuins are enzymes associated with the effects of calorie restriction, and they are NAD⁺-dependent — they cannot work without it. So NMN supplies the fuel by raising NAD⁺, and resveratrol was proposed to press the pedal by activating SIRT1. Put them together and the stack sells itself.
What each has behind it in humans is where the two part company.
What NMN has
A consistent biomarker result and a thin outcome record. In a randomized, double-blind, placebo-controlled trial of 80 healthy middle-aged adults (n = 80) taking 300, 600 or 900 mg daily for 60 days, blood NAD rose significantly in every dose group at day 30 and day 60 against both placebo and baseline (all p ≤ 0.001) [1].
The best clinical result is narrow and real: in postmenopausal women with prediabetes who were overweight or obese, 10 weeks of NMN increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp, with no change on placebo[2]. Pooled across eight randomized trials in 342 mostly non-diabetic adults, though, NMN produced no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or the lipid profile [3].
Summed up: NMN does the mechanistic thing reliably and the clinical thing rarely — the same pattern that runs through the NAD⁺ benefits evidence generally, and the reason we compare it with nicotinamide riboside rather than with anything outside the category.
What resveratrol has, in three trials
Resveratrol’s human record is older, larger and far more contradictory. Three trials tell the story.
The encouraging one. Eleven healthy obese men took 150 mg a day of resveratrol and placebo for 30 days in a randomized double-blind crossover. Resveratrol significantly reduced sleeping and resting metabolic rate, activated AMPK in muscle, raised SIRT1 and PGC-1α protein, improved muscle mitochondrial respiration on a fatty acid substrate, lowered intrahepatic lipid, circulating glucose, triglycerides and inflammation markers, dropped systolic blood pressure and improved the HOMA index — changes the authors described as mimicking calorie restriction [4]. Eleven men, one month.
The null one. Twenty-four obese but otherwise healthy men were randomized to four weeks of high-dose resveratrol or placebo, with insulin sensitivity by hyperinsulinemic-euglycemic clamp as the primary outcome. It deteriorated insignificantly in both groups. Endogenous glucose production and glucose turnover and oxidation were unchanged; there was no effect on blood pressure, resting energy expenditure, lipid oxidation, ectopic or visceral fat, or inflammatory and metabolic biomarkers. The authors wrote that the lack of effect “raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders”[5].
The one nobody quotes. Twenty-seven healthy, physically inactive men around 65 were randomized to eight weeks of 250 mg trans-resveratrol daily (n = 14) or placebo (n = 13) alongside high-intensity exercise training. Exercise produced a 45% greater increase in maximal oxygen uptake in the placebo group than in the resveratrol group(P < 0.05), and mean arterial pressure fell in the placebo group only. Resveratrol also abolished the positive effects of exercise on LDL, the total-to-HDL cholesterol ratio and triglycerides. SIRT1 protein levels were not affected by resveratrol at all [6].
That last finding deserves to be sat with. In the trial that tested the mechanism directly, resveratrol did not raise SIRT1 protein — and it made a proven intervention work worse.
Nobody has compared them
We looked for the trial that would settle the stack question. On September 13, 2026, a PubMed search for nicotinamide mononucleotide versus resveratrol randomized trial returned zero results, and a search for nicotinamide mononucleotide resveratrol head-to-head comparison humans returned zero results. As a control, a search for nicotinamide mononucleotide randomized controlled trial returned 32, so the instrument was working when the other two came back empty.
There is no published head-to-head. Anyone telling you which of the two is better is reasoning from mechanism, not reporting a result.
What about taking both?
The combination has been studied, though not in the form the stacks sell. One paper paired a low resveratrol dose (50 mg) with leucine (1.11 g) in a four-week placebo-controlled trial of 36 prediabetic subjects and reported a 33% reduction in HOMA-IR with corresponding falls in glucose and insulin area under the curve on oral glucose tolerance testing. The NAD⁺ precursor arm of the same paper — nicotinic acid, NMN and nicotinamide riboside synergizing with leucine — was done entirely in cells, in C. elegans and in a mouse model of atherosclerosis [7].
So the human half of that study is about resveratrol and leucine, not about NMN. Read carefully, it is evidence for a different product than the one it gets cited to support.
How we would choose
If the goal is raising NAD⁺, NMN is the one with a consistent, dose-dependent human result, and NR has an even longer record. Resveratrol has not been shown to raise NAD⁺ and is not a precursor; it was proposed as a switch, and the trial that measured the switch found it unmoved.
If the goal is a measurable health outcome, neither molecule has earned the confidence the stacks project, and resveratrol carries a specific caution NMN does not — one trial in which it made exercise training less effective in exactly the age group most likely to buy it.
And whichever way you lean, compare on cost per gram of the actual active ingredient before you buy a blend that lists both. Our price comparison and cost calculator exist to make that comparison possible, and the cheapest format in this category is still the one carrying the best data — an oral precursor.